<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7780">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00889330</url>
  </required_header>
  <id_info>
    <org_study_id>09-003-05</org_study_id>
    <nct_id>NCT00889330</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of a Eye Drop for Eye Allergy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vistakon Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vistakon Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of an anti-allergy eyedrop.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Ocular Itching at Visit 3 (Day 0) at 7 Minutes Following Allergen Challenge, 16 Hours After Treatment Instillation.</measure>
    <time_frame>Visit 3 (Day 0) 16 hours post-dose, at up to 7 minutes following Allergen Challenge</time_frame>
    <safety_issue>No</safety_issue>
    <description>A 0 to 4 scale used, allowing for half increment scores, where 0 indicates &quot;none&quot; and 4 indicates &quot;incapacitating itch with an irresistible urge to rub&quot;; measurement taken at up to 7 minutes following allergen challenge, 16 hours post treatment instillation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Conjunctival Redness at Visit 3 (Day 0) at 20 Minutes Following Allergen Challenge, 16 Hours After Treatment Instillation</measure>
    <time_frame>Visit 3 (Day 0) At 20 minutes following Allergen Challenge, 16 hours post-treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>A 0 to 4 scale used, allowing for half increment scores to measure redness, where 0 indicates &quot;none&quot; and 4 indicates &quot;extremely red&quot;; measurement taken at 20 minutes following allergen challenge, 16 hours post treatment instillation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Itching at Visit 4 (Day 14) at 7 Minutes Following Allergen Challenge, 15 Minutes Post- Treatment Instillation</measure>
    <time_frame>Visit 4 (Day 14) up to 7 minutes following Allergen Challenge</time_frame>
    <safety_issue>No</safety_issue>
    <description>0 to 4 scale, allowing for half increment scores, where 0 indicates &quot;none&quot; and 4 indicates &quot;incapacitating itch with an irresistible urge to rub&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Conjunctival Redness at Visit 4 (Day 14) at 20 Minutes Following Allergen Challenge, 15 Minutes Post Treatment Instillation</measure>
    <time_frame>Visit 4 (Day 14) At 20 minutes following Allergen Challenge</time_frame>
    <safety_issue>No</safety_issue>
    <description>A 0 to 4 scale used, allowing for half increment scores to measure redness, where 0 indicates &quot;none&quot; and 4 indicates &quot;extremely red&quot;; measurement taken at 20 minutes following allergen challenge, 16 hours post treatment instillation.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Number of Eyes With a Visual Acuity Change From Visit 1 (Day -21) at Day -14</measure>
    <time_frame>Visit 2 (Day -14) pre-allergen challenge</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The number of eyes with any change in visual acuity measurements compared to Day -21.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Eyes With a Visual Acuity Change From Visit 1 (Day -21) at Day 0 Pre-dose, Pre-allergen Challenge</measure>
    <time_frame>Visit 3 (Day 0) pre-dose, pre-allergen challenge</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The number of eyes with any change in visual acuity measurements compared to Day -21</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Eyes With a Visual Acuity Change From Visit 1 (Day -21) at Day 14 Pre-dose, Pre-allergen Challenge</measure>
    <time_frame>Visit 4 (Day 14) pre-dose, pre-allergen challenge</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The number of eyes with any change in visual acuity measurements compared to Day -21</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Eyes With a Undilated Fundoscopy Changes From Visit 1 (Day -21) at Day 14</measure>
    <time_frame>Visit 4 (Day 14) pre-dose, pre-allergen challenge</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The number of eyes with any change to the following: Vitreous, Retina, Macula, Choroid, Optic Nerve</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Eyes With Slit Lamp Biomicroscopy Changes From Visit 1 (Day -21) at Day -14</measure>
    <time_frame>Visit 2 (Day -14) pre-allergen challenge</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The number of eyes with any change in the following: anterior chamber, conjunctiva, cornea, iris, lens, lids, tear meniscus</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Eyes With Slit Lamp Biomicroscopy Changes From Visit 1 (Day -21) at Day 0 Pre-dose, Pre-allergen Challenge</measure>
    <time_frame>Visit 3 (Day 0) pre-dose, pre-allergen challenge</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The number of eyes with any change in the following: anterior chamber, conjunctiva, cornea, iris, lens, lids, tear meniscus</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Eyes With Slit Lamp Biomicroscopy Changes From Visit 1 (Day -21) at Day 0 Post-dose, Pre-allergen Challenge</measure>
    <time_frame>Visit 3 (Day 0) post-dose, pre-allergen challenge</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The number of eyes with any change in the following: anterior chamber, conjunctiva, cornea, iris, lens, lids, tear meniscus</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Eyes With Slit Lamp Biomicroscopy Changes From Visit 1 (Day -21) at Day 14 Pre-dose, Pre-allergen Challenge</measure>
    <time_frame>Visit 4 (Day 14) pre-dose, pre-allergen challenge</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The number of eyes with any change in the following: anterior chamber, conjunctiva, cornea, iris, lens, lids, tear meniscus</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Eyes With Slit Lamp Biomicroscopy Changes From Visit 1 (Day -21) at Day 14 Post-dose, Pre-allergen Challenge</measure>
    <time_frame>Visit 4 (Day 14) post-dose, pre-allergen challenge</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The number of eyes with any change in the following: anterior chamber, conjunctiva, cornea, iris, lens, lids, tear meniscus</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Allergic Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>alcaftadine ophthalmic solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>active treatment: administered as a single one-drop dose in each eye at each visit (Day 0 and Day 14).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>inactive ophthalmic solution vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, vehicle: administered as a single one-drop dose in each eye at each visit (Day 0 and Day 14).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alcaftadine</intervention_name>
    <description>0.25% Ophthalmic Solution, one drop in each eye at each of two visits.</description>
    <arm_group_label>alcaftadine ophthalmic solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vehicle without active, one drop in each eye at each of two visits.</description>
    <arm_group_label>inactive ophthalmic solution vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 10 years of age

          -  positive history of ocular allergies

          -  positive skin test reaction to allergens.

        Exclusion Criteria:

          -  known allergy, contraindication, or sensitivities to the use of any of the study
             medication(s) or their components

          -  ocular surgical intervention within three (3) months prior to visit 1 or during the
             study

          -  known history of retinal detachment, diabetic retinopathy, or progressive retinal
             disease, or glaucoma

          -  any other significant illness
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Fairfield</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mason</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <lastchanged_date>February 18, 2015</lastchanged_date>
  <firstreceived_date>April 24, 2009</firstreceived_date>
  <firstreceived_results_date>June 24, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alcaftadine</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Alcaftadine Ophthalmic Solution</title>
          <description>active treatment: administered as a single dose of one drop per eye at each of two visits, Day 0 and Day 14.</description>
        </group>
        <group group_id="P2">
          <title>Inactive Vehicle Ophthalmic Solution</title>
          <description>inactive treatment: administered as a single dose of one drop per eye at each of two visits, Day 0 and Day 14.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Alcaftadine Ophthalmic Solution</title>
          <description>active treatment: administered as a single dose of one drop per eye at each of two visits, Day 0 and Day 14.</description>
        </group>
        <group group_id="B2">
          <title>Inactive Vehicle Ophthalmic Solution</title>
          <description>inactive treatment: administered as a single dose of one drop per eye at each of two visits, Day 0 and Day 14.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
                <measurement group_id="B2" value="30"/>
                <measurement group_id="B3" value="60"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="37.8" spread="13.52"/>
                <measurement group_id="B2" value="34.3" spread="15.64"/>
                <measurement group_id="B3" value="36.1" spread="40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="36"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="24"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
                <measurement group_id="B2" value="30"/>
                <measurement group_id="B3" value="60"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ocular Itching at Visit 3 (Day 0) at 7 Minutes Following Allergen Challenge, 16 Hours After Treatment Instillation.</title>
        <description>A 0 to 4 scale used, allowing for half increment scores, where 0 indicates &quot;none&quot; and 4 indicates &quot;incapacitating itch with an irresistible urge to rub&quot;; measurement taken at up to 7 minutes following allergen challenge, 16 hours post treatment instillation.</description>
        <time_frame>Visit 3 (Day 0) 16 hours post-dose, at up to 7 minutes following Allergen Challenge</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Alcaftadine Ophthalmic Solution</title>
            <description>active treatment: administered as a single dose of one drop per eye at each of two visits, Day 0 and Day 14.</description>
          </group>
          <group group_id="O2">
            <title>Inactive Vehicle Ophthalmic Solution</title>
            <description>inactive treatment: administered as a single dose of one drop per eye at each of two visits, Day 0 and Day 14.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Ocular Itching at Visit 3 (Day 0) at 7 Minutes Following Allergen Challenge, 16 Hours After Treatment Instillation.</title>
            <description>A 0 to 4 scale used, allowing for half increment scores, where 0 indicates &quot;none&quot; and 4 indicates &quot;incapacitating itch with an irresistible urge to rub&quot;; measurement taken at up to 7 minutes following allergen challenge, 16 hours post treatment instillation.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.69" spread="0.691"/>
                  <measurement group_id="O2" value="2.27" spread="0.970"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Conjunctival Redness at Visit 3 (Day 0) at 20 Minutes Following Allergen Challenge, 16 Hours After Treatment Instillation</title>
        <description>A 0 to 4 scale used, allowing for half increment scores to measure redness, where 0 indicates &quot;none&quot; and 4 indicates &quot;extremely red&quot;; measurement taken at 20 minutes following allergen challenge, 16 hours post treatment instillation.</description>
        <time_frame>Visit 3 (Day 0) At 20 minutes following Allergen Challenge, 16 hours post-treatment</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Alcaftadine Ophthalmic Solution</title>
            <description>active treatment: administered as a single dose of one drop per eye at each of two visits, Day 0 and Day 14.</description>
          </group>
          <group group_id="O2">
            <title>Inactive Vehicle Ophthalmic Solution</title>
            <description>inactive treatment: administered as a single dose of one drop per eye at each of two visits, Day 0 and Day 14.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Conjunctival Redness at Visit 3 (Day 0) at 20 Minutes Following Allergen Challenge, 16 Hours After Treatment Instillation</title>
            <description>A 0 to 4 scale used, allowing for half increment scores to measure redness, where 0 indicates &quot;none&quot; and 4 indicates &quot;extremely red&quot;; measurement taken at 20 minutes following allergen challenge, 16 hours post treatment instillation.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.96" spread="0.846"/>
                  <measurement group_id="O2" value="2.50" spread="0.579"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ocular Itching at Visit 4 (Day 14) at 7 Minutes Following Allergen Challenge, 15 Minutes Post- Treatment Instillation</title>
        <description>0 to 4 scale, allowing for half increment scores, where 0 indicates &quot;none&quot; and 4 indicates &quot;incapacitating itch with an irresistible urge to rub&quot;</description>
        <time_frame>Visit 4 (Day 14) up to 7 minutes following Allergen Challenge</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Alcaftadine Ophthalmic Solution</title>
            <description>active treatment: administered as a single dose of one drop per eye at each of two visits, Day 0 and Day 14.</description>
          </group>
          <group group_id="O2">
            <title>Inactive Vehicle Ophthalmic Solution</title>
            <description>inactive treatment: administered as a single dose of one drop per eye at each of two visits, Day 0 and Day 14.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Ocular Itching at Visit 4 (Day 14) at 7 Minutes Following Allergen Challenge, 15 Minutes Post- Treatment Instillation</title>
            <description>0 to 4 scale, allowing for half increment scores, where 0 indicates &quot;none&quot; and 4 indicates &quot;incapacitating itch with an irresistible urge to rub&quot;</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.42" spread="0.509"/>
                  <measurement group_id="O2" value="1.90" spread="1.058"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Conjunctival Redness at Visit 4 (Day 14) at 20 Minutes Following Allergen Challenge, 15 Minutes Post Treatment Instillation</title>
        <description>A 0 to 4 scale used, allowing for half increment scores to measure redness, where 0 indicates &quot;none&quot; and 4 indicates &quot;extremely red&quot;; measurement taken at 20 minutes following allergen challenge, 16 hours post treatment instillation.</description>
        <time_frame>Visit 4 (Day 14) At 20 minutes following Allergen Challenge</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Alcaftadine Ophthalmic Solution</title>
            <description>active treatment: administered as a single dose of one drop per eye at each of two visits, Day 0 and Day 14.</description>
          </group>
          <group group_id="O2">
            <title>Inactive Vehicle Ophthalmic Solution</title>
            <description>inactive treatment: administered as a single dose of one drop per eye at each of two visits, Day 0 and Day 14.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Conjunctival Redness at Visit 4 (Day 14) at 20 Minutes Following Allergen Challenge, 15 Minutes Post Treatment Instillation</title>
            <description>A 0 to 4 scale used, allowing for half increment scores to measure redness, where 0 indicates &quot;none&quot; and 4 indicates &quot;extremely red&quot;; measurement taken at 20 minutes following allergen challenge, 16 hours post treatment instillation.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.57" spread="0.863"/>
                  <measurement group_id="O2" value="2.15" spread="0.822"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Eyes With a Visual Acuity Change From Visit 1 (Day -21) at Day -14</title>
        <description>The number of eyes with any change in visual acuity measurements compared to Day -21.</description>
        <time_frame>Visit 2 (Day -14) pre-allergen challenge</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Alcaftadine Ophthalmic Solution</title>
            <description>active treatment: administered as a single dose of one drop per eye at each of two visits, Day 0 and Day 14.</description>
          </group>
          <group group_id="O2">
            <title>Inactive Vehicle Ophthalmic Solution</title>
            <description>inactive treatment: administered as a single dose of one drop per eye at each of two visits, Day 0 and Day 14.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Eyes With a Visual Acuity Change From Visit 1 (Day -21) at Day -14</title>
            <description>The number of eyes with any change in visual acuity measurements compared to Day -21.</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Eyes With a Visual Acuity Change From Visit 1 (Day -21) at Day 0 Pre-dose, Pre-allergen Challenge</title>
        <description>The number of eyes with any change in visual acuity measurements compared to Day -21</description>
        <time_frame>Visit 3 (Day 0) pre-dose, pre-allergen challenge</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Alcaftadine Ophthalmic Solution</title>
            <description>active treatment: administered as a single dose of one drop per eye at each of two visits, Day 0 and Day 14.</description>
          </group>
          <group group_id="O2">
            <title>Inactive Vehicle Ophthalmic Solution</title>
            <description>inactive treatment: administered as a single dose of one drop per eye at each of two visits, Day 0 and Day 14.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Eyes With a Visual Acuity Change From Visit 1 (Day -21) at Day 0 Pre-dose, Pre-allergen Challenge</title>
            <description>The number of eyes with any change in visual acuity measurements compared to Day -21</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Eyes With a Visual Acuity Change From Visit 1 (Day -21) at Day 14 Pre-dose, Pre-allergen Challenge</title>
        <description>The number of eyes with any change in visual acuity measurements compared to Day -21</description>
        <time_frame>Visit 4 (Day 14) pre-dose, pre-allergen challenge</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Alcaftadine Ophthalmic Solution</title>
            <description>active treatment: administered as a single dose of one drop per eye at each of two visits, Day 0 and Day 14.</description>
          </group>
          <group group_id="O2">
            <title>Inactive Vehicle Ophthalmic Solution</title>
            <description>inactive treatment: administered as a single dose of one drop per eye at each of two visits, Day 0 and Day 14.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Eyes With a Visual Acuity Change From Visit 1 (Day -21) at Day 14 Pre-dose, Pre-allergen Challenge</title>
            <description>The number of eyes with any change in visual acuity measurements compared to Day -21</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Eyes With a Undilated Fundoscopy Changes From Visit 1 (Day -21) at Day 14</title>
        <description>The number of eyes with any change to the following: Vitreous, Retina, Macula, Choroid, Optic Nerve</description>
        <time_frame>Visit 4 (Day 14) pre-dose, pre-allergen challenge</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Alcaftadine Ophthalmic Solution</title>
            <description>active treatment: administered as a single dose of one drop per eye at each of two visits, Day 0 and Day 14.</description>
          </group>
          <group group_id="O2">
            <title>Inactive Vehicle Ophthalmic Solution</title>
            <description>inactive treatment: administered as a single dose of one drop per eye at each of two visits, Day 0 and Day 14.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Eyes With a Undilated Fundoscopy Changes From Visit 1 (Day -21) at Day 14</title>
            <description>The number of eyes with any change to the following: Vitreous, Retina, Macula, Choroid, Optic Nerve</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Vitreous</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Retina</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Macula</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Choroid</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Optic Nerve</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Eyes With Slit Lamp Biomicroscopy Changes From Visit 1 (Day -21) at Day -14</title>
        <description>The number of eyes with any change in the following: anterior chamber, conjunctiva, cornea, iris, lens, lids, tear meniscus</description>
        <time_frame>Visit 2 (Day -14) pre-allergen challenge</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Alcaftadine Ophthalmic Solution</title>
            <description>active treatment: administered as a single dose of one drop per eye at each of two visits, Day 0 and Day 14.</description>
          </group>
          <group group_id="O2">
            <title>Inactive Vehicle Ophthalmic Solution</title>
            <description>inactive treatment: administered as a single dose of one drop per eye at each of two visits, Day 0 and Day 14.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Eyes With Slit Lamp Biomicroscopy Changes From Visit 1 (Day -21) at Day -14</title>
            <description>The number of eyes with any change in the following: anterior chamber, conjunctiva, cornea, iris, lens, lids, tear meniscus</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>anterior chamber</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>conjunctiva</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>cornea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>iris</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>lens</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>lids</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>tear meniscus</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Eyes With Slit Lamp Biomicroscopy Changes From Visit 1 (Day -21) at Day 0 Pre-dose, Pre-allergen Challenge</title>
        <description>The number of eyes with any change in the following: anterior chamber, conjunctiva, cornea, iris, lens, lids, tear meniscus</description>
        <time_frame>Visit 3 (Day 0) pre-dose, pre-allergen challenge</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Alcaftadine Ophthalmic Solution</title>
            <description>active treatment: administered as a single dose of one drop per eye at each of two visits, Day 0 and Day 14.</description>
          </group>
          <group group_id="O2">
            <title>Inactive Vehicle Ophthalmic Solution</title>
            <description>inactive treatment: administered as a single dose of one drop per eye at each of two visits, Day 0 and Day 14.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Eyes With Slit Lamp Biomicroscopy Changes From Visit 1 (Day -21) at Day 0 Pre-dose, Pre-allergen Challenge</title>
            <description>The number of eyes with any change in the following: anterior chamber, conjunctiva, cornea, iris, lens, lids, tear meniscus</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>anterior chamber</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>conjunctiva</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>cornea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>iris</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>lens</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>lids</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>tear meniscus</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Eyes With Slit Lamp Biomicroscopy Changes From Visit 1 (Day -21) at Day 0 Post-dose, Pre-allergen Challenge</title>
        <description>The number of eyes with any change in the following: anterior chamber, conjunctiva, cornea, iris, lens, lids, tear meniscus</description>
        <time_frame>Visit 3 (Day 0) post-dose, pre-allergen challenge</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Alcaftadine Ophthalmic Solution</title>
            <description>active treatment: administered as a single dose of one drop per eye at each of two visits, Day 0 and Day 14.</description>
          </group>
          <group group_id="O2">
            <title>Inactive Vehicle Ophthalmic Solution</title>
            <description>inactive treatment: administered as a single dose of one drop per eye at each of two visits, Day 0 and Day 14.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Eyes With Slit Lamp Biomicroscopy Changes From Visit 1 (Day -21) at Day 0 Post-dose, Pre-allergen Challenge</title>
            <description>The number of eyes with any change in the following: anterior chamber, conjunctiva, cornea, iris, lens, lids, tear meniscus</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>anterior chamber</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>conjunctiva</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>cornea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>iris</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>lens</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>lids</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>tear meniscus</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Eyes With Slit Lamp Biomicroscopy Changes From Visit 1 (Day -21) at Day 14 Pre-dose, Pre-allergen Challenge</title>
        <description>The number of eyes with any change in the following: anterior chamber, conjunctiva, cornea, iris, lens, lids, tear meniscus</description>
        <time_frame>Visit 4 (Day 14) pre-dose, pre-allergen challenge</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Alcaftadine Ophthalmic Solution</title>
            <description>active treatment: administered as a single dose of one drop per eye at each of two visits, Day 0 and Day 14.</description>
          </group>
          <group group_id="O2">
            <title>Inactive Vehicle Ophthalmic Solution</title>
            <description>inactive treatment: administered as a single dose of one drop per eye at each of two visits, Day 0 and Day 14.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Eyes With Slit Lamp Biomicroscopy Changes From Visit 1 (Day -21) at Day 14 Pre-dose, Pre-allergen Challenge</title>
            <description>The number of eyes with any change in the following: anterior chamber, conjunctiva, cornea, iris, lens, lids, tear meniscus</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>anterior chamber</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>conjunctiva</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>cornea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>iris</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>lens</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>lids</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>tear meniscus</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Eyes With Slit Lamp Biomicroscopy Changes From Visit 1 (Day -21) at Day 14 Post-dose, Pre-allergen Challenge</title>
        <description>The number of eyes with any change in the following: anterior chamber, conjunctiva, cornea, iris, lens, lids, tear meniscus</description>
        <time_frame>Visit 4 (Day 14) post-dose, pre-allergen challenge</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Alcaftadine Ophthalmic Solution</title>
            <description>active treatment: administered as a single dose of one drop per eye at each of two visits, Day 0 and Day 14.</description>
          </group>
          <group group_id="O2">
            <title>Inactive Vehicle Ophthalmic Solution</title>
            <description>inactive treatment: administered as a single dose of one drop per eye at each of two visits, Day 0 and Day 14.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of eyes analyzed</title>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Eyes With Slit Lamp Biomicroscopy Changes From Visit 1 (Day -21) at Day 14 Post-dose, Pre-allergen Challenge</title>
            <description>The number of eyes with any change in the following: anterior chamber, conjunctiva, cornea, iris, lens, lids, tear meniscus</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>anterior chamber</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>conjunctiva</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>cornea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>iris</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>lens</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>lids</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>tear meniscus</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Alcaftadine Ophthalmic Solution</title>
          <description>active treatment: administered as a single dose of one drop per eye at each of two visits, Day 0 and Day 14.</description>
        </group>
        <group group_id="E2">
          <title>Inactive Vehicle Ophthalmic Solution</title>
          <description>inactive treatment: administered as a single dose of one drop per eye at each of two visits, Day 0 and Day 14.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Arthur Shedden, MD</name_or_title>
      <organization>Johnson &amp; Johnson Vision Care, Inc.</organization>
      <phone>904-443-1557</phone>
      <email>ashedden@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
